NCT05548946 A Dimensional Model for Personality Disorders in Later Life
| NCT ID | NCT05548946 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitair Ziekenhuis Brussel |
| Condition | Psychiatric Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 750 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2025-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 750 participants in total. It began in 2022-09-01 with a primary completion date of 2025-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Research on personality disorders (PDs) in older adults is currently limited. This is surprising, given that PDs are also common in this age group. Moreover, PDs show high co-morbidity with other disorders (both mental and physical) and often have a negative effect on treatment. With this in mind, the conceptualization, diagnosis and treatment of PDs in older adults represents an important task for mental health care. To this end, problems with the current classification of PDs need to be tackled, as they currently complicate this task. The current DSM-5 (Diagnostic and Statistical Manual, Edition 5) (APA, 2013) categorical PD criteria are mainly based on the living conditions of younger adults and are therefore often not suited for PD diagnosis in older adults. Currently, however, a paradigm shift is taking place from a categorical to a dimensional approach of PDs. The "Alternative Model for Personality Disorders" (AMPD) (APA, 2013) and the approach by ICD-11 (International Classification of Diseases 11th Revision) (WHO, 2019) are examples of new, dimensional models for PDs. These models conceptualize PDs using two dimensional criteria: (1) criterion A, which captures the overall level of personality (dis)functioning and (2) criterion B which describes the PD style by pathological/maladaptive personality traits. This paradigm shift offers the possibility to give the aging context the attention it deserves, by examining the suitability of this new dimensional conceptualization of PD among older adults. The goal of this research is to examine whether the combined AMPD and ICD-11 dimensional approach is appropriate for use in older adults. This will be done by administering instruments capturing criterion A and B in the general population in younger (18-64) and older (65 and older) adults to evaluate their age-neutrality, as well as in a clinical sample of older (65 and older) adults, to empirically evaluate its clinical relevance in later life.
Eligibility Criteria
Clinical population (inpatients and outpatients) Inclusion Criteria: * ONLY older adults: from the age of 65 * Dutch speaking Exclusion Criteria (as evaluated by the psychiatrists and psychologists of the participating institutions): * Severe cognitive impairment (Patients who are admitted because of cognitive impairment will be excluded from the participant pool, other than this the psychiatrists and psychologists of the participating institutions will make an evaluation of the patients' cognitive capacities) * Acute state of mental impairment which would interfere with the reliability of the patients' responses (for example severe psychosis), as evaluated by the psychiatrists and psychologist of the participating institutions.
Contact & Investigator
Morag Facon
PRINCIPAL INVESTIGATOR
Vrije Universiteit Brussel
Frequently Asked Questions
Who can join the NCT05548946 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Psychiatric Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05548946 currently recruiting?
Yes, NCT05548946 is actively recruiting participants. Contact the research team at morag.flora.facon@vub.be for enrollment information.
Where is the NCT05548946 trial being conducted?
This trial is being conducted at Tienen, Belgium, Heerlen, Netherlands.
Who is sponsoring the NCT05548946 clinical trial?
NCT05548946 is sponsored by Universitair Ziekenhuis Brussel. The principal investigator is Morag Facon at Vrije Universiteit Brussel. The trial plans to enroll 750 participants.